# Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)

> **NCT01019928** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 14 (actual)

## Conditions studied

- Sensitivity in Esophagus

## Interventions

- **DRUG:** AZD1386
- **DRUG:** Placebo to AZD1386

## Key facts

- **NCT ID:** NCT01019928
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2012-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01019928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01019928, "Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01019928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*